Open Access

[Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway

  • Authors:
    • Jianjie Zhao
    • Zhirong Li
    • Yi Chen
    • Shu Zhang
    • Lingji Guo
    • Bo Gao
    • Yan Jiang
    • Wuguo Tian
    • Shuai Hao
    • Xiaohua Zhang
  • View Affiliations

  • Published online on: May 30, 2022     https://doi.org/10.3892/ijo.2022.5376
  • Article Number: 86
  • Copyright : © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

July-2022
Volume 61 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao J, Li Z, Chen Y, Zhang S, Guo L, Gao B, Jiang Y, Tian W, Hao S, Zhang X, Zhang X, et al: [Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. Int J Oncol 61: 86, 2022
APA
Zhao, J., Li, Z., Chen, Y., Zhang, S., Guo, L., Gao, B. ... Zhang, X. (2022). [Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. International Journal of Oncology, 61, 86. https://doi.org/10.3892/ijo.2022.5376
MLA
Zhao, J., Li, Z., Chen, Y., Zhang, S., Guo, L., Gao, B., Jiang, Y., Tian, W., Hao, S., Zhang, X."[Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway". International Journal of Oncology 61.1 (2022): 86.
Chicago
Zhao, J., Li, Z., Chen, Y., Zhang, S., Guo, L., Gao, B., Jiang, Y., Tian, W., Hao, S., Zhang, X."[Retracted] MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway". International Journal of Oncology 61, no. 1 (2022): 86. https://doi.org/10.3892/ijo.2022.5376